Tag Archives: says

AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder.  The Institute for Clinical and… Read More »

J&J commits to end sale of opioids nationwide in $230 million settlement, New York AG says

New York State Attorney General, Letitia James, speaks during a news conference, to announce criminal justice reform in New York City, U.S., May 21, 2021. Brendan McDermid | Reuters New York Attorney General Letitia James announced on Saturday that Johnson & Johnson has agreed to end the manufacture and sale of opioids nationwide in a $… Read More »

Biden says delta Covid variant is ‘particularly dangerous’ for young people

President Joe Biden speaks about reaching 300 million COVID-19 vaccination shots, in the State Dining Room of the White House, Friday, June 18, 2021, in Washington. Evan Vucci | AP President Joe Biden on Friday doubled down on his administration’s plea to Americans to get vaccinated against Covid-19 as quickly as possible, warning the highly… Read More »

Biogen’s $56K price on Aduhelm ‘simply unacceptable,’ Alzheimer’s Association says after vouching for FDA approval

Biogen’s decision to price its historic Alzheimer’s drug Aduhelm at a whopping $ 56,000 per year unsurprisingly irked lawmakers in Washington D.C., but it’s now drawing criticism from the drugmaker’s own allies as well.  The Alzheimer’s Association, a leading advocate for Aduhelm’s FDA approval, said in a Saturday statement that the drug’s list price is “simply… Read More »